Trastuzumab deruxtecan in HER2-positive metastatic breast cancer patients with brain metastases: A DESTINY-Breast01 subgroup analysis Journal Article
| Authors: | Jerusalem, G.; Park, Y. H.; Yamashita, T.; Hurvitz, S. A.; Modi, S.; Andre, F.; Krop, I. E.; Farré, X. G.; You, B.; Saura, C.; Kim, S. B.; Osborne, C. R.; Murthy, R. K.; Gianni, L.; Takano, T.; Liu, Y.; Cathcart, J.; Lee, C.; Perrin, C. |
| Article Title: | Trastuzumab deruxtecan in HER2-positive metastatic breast cancer patients with brain metastases: A DESTINY-Breast01 subgroup analysis |
| Abstract: | DESTINY-Breast01 (NCT03248492) evaluated trastuzumab deruxtecan (T-DXd; DS-8201) in patients with heavily pretreated HER2-positive metastatic breast cancer (mBC). We present a subgroup of 24 patients with a history of treated brain metastases (BM), a population with limited treatment options. In patients with BMs, the confirmed objective response rate (cORR) was 58.3% [95% confidence interval (CI), 36.6%–77.9%], and the median progression-free survival (mPFS) was 18.1 months (95% CI, 6.7–18.1 months). In patients without BMs (n = 160), cORR was 61.3% and mPFS was 16.4 months. Eight patients (47.1%) experienced a best overall intracranial response of partial response or complete response. Seven patients (41.2%) had a best percentage change in brain lesion diameter from baseline consistent with stable disease. Two patients (8.3%) with BMs and two (1.3%) without BMs experienced progression in the brain. The safety profile of T-DXd was consistent with previous studies. The durable clinical activity of T-DXd in this population warrants further investigation. © 2022 The Authors;. |
| Keywords: | adult; cancer survival; clinical article; treatment outcome; treatment response; major clinical study; overall survival; drug efficacy; drug safety; capecitabine; cancer patient; nuclear magnetic resonance imaging; brain tumor; brain neoplasms; metastasis; progression free survival; phase 2 clinical trial; tumor volume; epidermal growth factor receptor 2; camptothecin; pathology; breast neoplasms; pneumonia; axillary lymph node; in situ hybridization; acute kidney failure; multicenter study; breast tumor; brain metastasis; remission; glucocorticoid; receptor, erbb-2; craniotomy; interstitial lung disease; stereotactic radiosurgery; trastuzumab; metastatic breast cancer; lymphangitis; lapatinib; lymphocyte count; epidermal growth factor receptor kinase inhibitor; pertuzumab; whole brain radiotherapy; antibody conjugate; immunoconjugates; brain damage; metastasis resection; human epidermal growth factor receptor 2 positive breast cancer; humans; human; female; article; trastuzumab deruxtecan; acute liver failure |
| Journal Title: | Cancer Discovery |
| Volume: | 12 |
| Issue: | 12 |
| ISSN: | 2159-8274 |
| Publisher: | American Association for Cancer Research |
| Date Published: | 2022-12-01 |
| Start Page: | 2754 |
| End Page: | 2762 |
| Language: | English |
| DOI: | 10.1158/2159-8290.Cd-22-0837 |
| PUBMED: | 36255231 |
| PROVIDER: | scopus |
| PMCID: | PMC9716244 |
| DOI/URL: | |
| Notes: | Article -- Export Date: 3 January 2023 -- Source: Scopus |
